David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Stephen J. Schuster, MD, on CD19+ Lymphomas: Sustained Remissions in Relapsed or Refractory Disease

Stephen J. Schuster, MD, of the University of Pennsylvania, discusses the findings of a study of chimeric antigen receptor modified T cells directed against CD19 in patients with relapsed or refractory disease (Abstract 183).

Leukemia

Hagop M. Kantarjian, MD

Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine

Hagop M. Kantarjian, MD, of MD Anderson Cancer Center, discusses a study that compared efficacy and safety results of using 5-day and 10-day regimens of a novel hypomethylating agent in 103 treatment-naïve AML patients who were not candidates for intensive chemotherapy (Abstract 458).

Multiple Myeloma

S. Vincent Rajkumar, MD

S. Vincent Rajkumar, MD, on Multiple Myeloma: Newly Approved Drugs

S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes a special FDA-sponsored session on the three myeloma drugs that were approved this November––daratumumab, ixazomib, and elotozumab––and their current and future roles in treating the disease.

Multiple Myeloma

Sagar Lonial, MD

Sagar Lonial, MD, on Multiple Myeloma: How I Treat Newly Diagnosed Patients

Sagar Lonial, MD, of Emory University School of Medicine, summarizes his educational session on this vital topic.

Leukemia

Margaret O'Donnell, MD

Margaret O'Donnell, MD, on Novel Approaches to Treatment for Older AML Patients

Margaret O'Donnell, MD, of the City of Hope National Medical Center, summarizes a session on this vital topic (Session 613).

Feb

Today In Oncology

10-Year Outcomes With Adjuvant APBI Using Multicatheter Brachytherapy vs WBI After Breast-Conserving Surgery for Early Breast Cancer

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Stephen J. Schuster, MD, on CD19+ Lymphomas: Sustained Remissions in Relapsed or Refractory Disease

Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine

S. Vincent Rajkumar, MD, on Multiple Myeloma: Newly Approved Drugs

Sagar Lonial, MD, on Multiple Myeloma: How I Treat Newly Diagnosed Patients

Margaret O'Donnell, MD, on Novel Approaches to Treatment for Older AML Patients

What Can Be Learned From Negative Findings of Two Trials in Biliary Tract Cancer

Defensive Beliefs May Prevent Individuals From Partaking in Screening for Colorectal Cancer

Oncologists Look for Strong Health-Care Priorities in the State of the Union Address

Axatilimab for Refractory Chronic Graft-vs-Host Disease

10-Year Outcomes With Adjuvant APBI Using Multicatheter Brachytherapy vs WBI After Breast-Conserving Surgery for Early Breast Cancer